PMC10338053_01
Case 1: timeline illustrating the changes in therapeutic regimen in correlation with molecular and radiological findings. FISH, fluorescence in situ hybridization; dPCR, digital polymerase chain reaction; TTF, time to treatment failure; Mo., months; ctDNA, circulating tumor DNA; IHC, immunohistochemestry; NGS, next-generation sequencing; Brigatinib 180, brigatinib with a 180-mg daily dose regimen; B240, brigatinib with a 240-mg daily dose regimen; A+O, combined treatment with alectinib and osimertinib. In red, the treatments used when EGFR resistance mutation was identified.
fonc-13-1182558-g001.jpg
PMC10338053_01_fonc-13-1182558-g001.jpg
f1
Applied Technologies  for exon 19). As first-line treatment, the patient received crizotinib (250 mg twice daily) for 13 months until brain magnetic resonance imaging (MRI) revealed brain metastases. After 5 months of treatment with alectinib (600 mg twice daily), CT scan showed progression of lung lesions ( Figure 1 ).
PMC10338053_02
Case 2: timeline illustrating the changes in therapeutic regimen in correlation with molecular and radiological findings. NGS, next-generation sequencing; TTF, time to treatment failure; Mo., months; CT, chemotherapy. In red, the treatments used when EGFR resistance mutation was identified.
fonc-13-1182558-g002.jpg
PMC10338053_02_fonc-13-1182558-g002.jpg
f2
After 2 months, the CT scan revealed new lung opacities that were attributed to a lymphangitic carcinomatosis ( Figure 2 ).